The April 2012 National Adult Vaccination Program (NAVP) Summit will be a one-day conference in Washington, DC, focused on state and national policies that affect adult vaccination rates. The Summit will utilize the expertise of the attendees in roundtable breakouts sessions to assess the policy impact of the Affordable Care Act’s (ACA) requirement for essential health benefits (EHB) and specifically the category of “preventive and wellness services.”

**Program attendees will discuss:**
- State and national policy components of the ACA and the preventive and wellness services category of the EHB.
- Policy opportunities to link important national efforts from the Centers for Disease Control and Prevention/Advisory Committee on Immunization Practices, the Department of Health and Human Services, Area Agencies on Aging, and advocacy organizations focused on improving adult vaccination rates.
- Already identified and agreed-upon policy barriers for adult immunizations and formulate policy strategies for improving adult immunization rates that utilize factors driving high pediatric immunization rates yet are largely missing in the adult immunization policy space.

**Program attendees will:**
- Participate in roundtable breakout sessions to assess the policy of the ACA’s requirement for EHB that includes preventive and wellness services.
- Establish a call-to-action policy framework based on Summit findings to be the foundation for a 2013 invitational conference on improving vaccination rates for adults that will showcase promising and best practices from across the nation.
- Address challenges of the ACA on systems/processes/frameworks for all stakeholders.

**WEDNESDAY, APRIL 25, 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 PM–9:00 PM</td>
<td>Registration and Networking Reception</td>
</tr>
<tr>
<td></td>
<td>Independence Room</td>
</tr>
</tbody>
</table>

**THURSDAY, APRIL 26, 2012**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM–8:00 AM</td>
<td>Registration and Breakfast</td>
</tr>
<tr>
<td></td>
<td>Fairchild Room</td>
</tr>
<tr>
<td>8:00 AM–8:30 AM</td>
<td>Welcome</td>
</tr>
<tr>
<td></td>
<td>James Appleby, RPh, MPH, GSA Executive Director</td>
</tr>
<tr>
<td></td>
<td>Why We Are Here and Expectations for the Day</td>
</tr>
<tr>
<td></td>
<td>Annette Schmidt, GSA Director of Strategic Alliances</td>
</tr>
<tr>
<td>8:30 AM–9:00 AM</td>
<td>Introduction of the Workgroup and the Goals for the Day</td>
</tr>
<tr>
<td></td>
<td>R. Gordon Douglas, MD, NAVP Workgroup Chairperson</td>
</tr>
<tr>
<td></td>
<td>Adjunct Professor of Medicine, Weill Cornell Medical College</td>
</tr>
</tbody>
</table>
9:00 AM–9:50 AM  
**Current State of Adult Vaccination Policy**  
Gregory Poland, MD, Director, Vaccine Research Group, Mayo Clinic

9:50 AM–10:05 AM  
**Blackberry Break**

10:05 AM–11:00 AM  
**Adult Vaccination Policy Barriers and Evidence-Based Solutions**

- Putting a Framework in Place to Remove the Barriers to Full Adult Immunization in Michigan  
  Joseph Fortuna, MD, Vice-Chair, Michigan Primary Care Consortium

- Impact of the Affordable Care Act’s Essential Health Benefits and Insurance Exchanges on Adult Immunizations  
  Litjen (LJ) Tan, Director, Medicine and Public Health, American Medical Association

11:00 AM–12:30 PM  
**Working Roundtables: Delivering Sustainable Change Through Policy**  
Moderator:  
Patti Gasdek Manolakis, PharmD

- Health Care System/Affordable Care Act Framework/Essential Health Benefits Process  
  Facilitators:  
  - R. Gordon Douglas, MD, NAVP Workgroup Chairperson, Adjunct Professor of Medicine, Weill Cornell Medical College  
  - William Schaffner, MD, Professor and Chair, Department of Preventive Medicine, Vanderbilt University School of Medicine

- Impact of the Affordable Care Act’s Essential Health Benefits and Insurance Exchanges on Adult Immunizations  
  Facilitators:  
  - Stefan Gravenstein, MD, MPH, Professor of Medicine, Alpert Medical School of Brown University  
  - Walter A. Orenstein, MD, Professor of Medicine, School of Medicine, Associate Director, Emory Vaccine Center, Director, Emory Program for Vaccine Policy and Development

- Opportunities to Improve Adult Immunization Rates Through the Health Care Reform Policies of the Affordable Care Act and Essential Health Benefits  
  Facilitators:  
  - Barbara Resnick, PhD, RN, CRNP, Professor of Nursing, University of Maryland School of Nursing, GSA Liaison  
  - Paul Etkind, DrPH, MPH, Senior Director of Infectious Diseases, Community Health Team, National Association of County and City Health Officials

12:30 PM–2:10 PM  
**Working Lunch and Continued Working Roundtables**

2:10 PM–2:25 PM  
**Blackberry Break**

2:25 PM–3:25 PM  
**Roundtable Reports With Open Discussion**
3:25 PM–3:45 PM  Summary of the Day and Next Steps  
R. Gordon Douglas, MD, NAVP Workgroup Chairperson  
Adjunct Professor of Medicine, Weill Cornell Medical College

3:45 PM–4:00 PM  Closing Remarks  
James Appleby, GSA Executive Director

4:00 PM  Adjourn
Improving Older Adult Immunization and the Way of Sophia: A 12 Step Program
- or –
The Architecture of a New Meta-narrative

G.A. Poland, MD, MACP, FIDSA
Mary Lowell Leary Professor of Medicine
Director, Mayo Vaccine Research Group
Mayo Clinic
Rochester, MN, USA

Although deaths due to vaccine-preventable diseases (VPDs) in the United States occur 250- to 300-fold more often among adults than among children, adult immunization has suffered from fewer resources, less attention, and lower priority. Importantly, major population age structure shifts are occurring in all countries, particularly highly developed countries that will intensify the economic costs and severity of the morbidity and mortality due to VPDs among adults. For these reasons, significant attention and resources should be applied to improving adult immunization. This presentation will examine cultural biases that inform current efforts and which must be overcome; this information can be used to construct the architecture of a new meta-narrative by which to conceive, develop, and communicate the high priority of adult immunization with the goal of significantly improving adult immunization coverage rates. This presentation will challenge attendees’ current assumptions and biases, and provide novel ways of thinking about the problem, the issues, and the solutions.
Putting a Framework in Place to Remove the Barriers to Full Adult Immunization\(^1\) in Michigan

Joseph Fortuna, MD  
Vice-Chair  
Michigan Primary Care Consortium

The Michigan Primary Care Consortium (MPCC), a multi-stakeholder nonprofit organization with diverse professional and geographic membership, is focused on improving primary care in Michigan. MPCC has implemented a multi-stakeholder Adult Immunization Initiative (A-I-I) aimed at identification, quantification, analysis, and removal or mitigation of the major barriers to all adults in Michigan being fully immunized in accordance with the Centers for Disease Control and Prevention (CDC) Guidelines for Adult Immunization.\(^2,3\) The First Phase of the A-I-I was to calculate the annual full cost burden to Michigan for having failed to reach the goal of full adult immunization.\(^1\) The Second Phase was to convene representatives of all of the adult immunization stakeholders in Michigan for a day-long, professionally facilitated colloquium (The Second Plenary Session[SPS]), during which attendees heard from the CDC, the American Medical Association, and the Michigan community Health Department about their efforts. Subsequently seven workgroups developed feasible, high-level work plans for elimination/mitigation of one each of seven main categories of barriers to full adult immunization. The Third Phase of the A-I-I is the work now going on in each of fifteen+ field-level “Communities of Interest [COIs]” (aka “affinity groups”) to implement the work plans developed at the SPS. Among these COIs are the following: hospitals and health care systems, local public health departments, retail pharmacies, physicians, payers, legislators, community agencies, faith-based groups, business and industry, labor organizations, trade associations, etc. Each COI has an individual and an organizational champion and each COI will be held accountable for its progress and outcomes over the next 3 years. A professionally coordinated public communications effort also will be implemented to raise awareness around adult immunization and change provider, community, and patient culture regarding adult immunization in Michigan. MPCC is serving as the convener and coordinator of the A-I-I with the support of lead organizations in each of the COIs. An ongoing Fourth Phase of the A-I-I is contemplated during which the implementation interventions will be evaluated, course corrected, and communicated as requested to other areas of the country.

1. Full adult immunization is defined as every adult being fully immunized in an age-, gender-, and condition-appropriate manner as outlined in the CDC Adult Vaccination Guidelines (see #2 below).
Impact of the Affordable Care Act’s Essential Health Benefits and Insurance Exchanges on Adult Immunizations

Litjen (LJ) Tan, MS, PhD
Director, Medicine and Public Health
American Medical Association
Co-chair, National Influenza Vaccine Summit

Disclaimer…

The opinions expressed in this presentation are solely those of the presenter and do not necessarily represent the official positions of the American Medical Association nor the National Influenza Vaccine Summit

I have no relevant financial relationships with the manufacturer(s) of any commercial products(s) and/or provider(s) of commercial services discussed in this presentation

Benefits of Immunization Are Clear

- Arguably one of the top public health interventions of all time
- Tremendous reduction in mortality and morbidity attributed to immunization
- Vaccine-preventable disease rates in children in the US have been dramatically reduced; some are close to eradication
- Vaccines save money as well as lives
- Increasing interest in disease prevention in US
- Immunizations are an important preventive service
By Not Immunizing Adults Adequately…

- >50,000 adults die annually from pneumococcal disease, influenza, hepatitis B, HPV
- Hundreds of thousands more are hospitalized
- Significant cost burden to the US economy
  - Influenza alone estimated at $10 billion annually…

Other Ramifications Exist

- Beyond the impact to the health of the public, our ineffectiveness in immunizing adults:
  - Creates disincentive for manufacturers to enter the market
  - Leaves chronically ill vulnerable
    - Failure to include immunizations as part of adult preventive care for those chronically ill
  - Creates disparities in access to care
    - Absence of commitment exacerbates existing barriers to immunization for those in the lower socio-economic strata and for the racial and ethnic minorities

Other Ramifications Exist

- Leaves us vulnerable during times of crisis when the ability to reach 250 million adults with vaccines/medications is crucial
  - Pandemic influenza
- Our failure to successfully immunize adults in healthy times predicts our failure to immunize them in times of crisis…
Fundamental Problems With Adult Immunization

- Adult immunization is severely undervalued by public, insurers, and providers
- Access to adult vaccines is not robust
  - The infrastructure to deliver adult vaccinations is poor; progress made with 2009 H1N1 lost
  - There is very limited provider and public/private collaboration to support adults receiving vaccines and providers immunizing
- Payment for procuring and administering adult vaccines is inadequate
  - What does the ACA do for us?

Payment for Adult Vaccination Pre-ACA

- Third-party coverage often questioned
  - Co-pay varied
  - No clear decision process regarding which vaccines would be covered and when...
  - No clear methodology by CMS in deciding which vaccines to reimburse
  - Pediatrics: ACIP → VFC → reimbursed
  - Uninsured-underinsured adults?
    - “No vaccine for you, come back next year!”
    - Vaccine Nazi, circa 1996

Unsatisfactory Payment...

- RESULT?
  - Providers want to immunize but fear losing money by doing so
  - Increasing awareness and improving access meaningless if providers choose not to vaccinate
  - Public often confused about whether a vaccine will be paid for by insurance
    - May be deciding factor as to whether vaccine is sought
  - Payment for adult vaccination must be adequate and fair to all stakeholders
From an Internist…

“I have noticed that in administering vaccines, I am carrying a financial loss.… Because of this I am seriously considering not updating my patients’ vaccine after I am done with my current supply. I will just send my patients to the County Health Department to get their vaccines…

In reality, how many of these patients even have time to call the health department and fall in line to get their vaccine?”

Impact of the Patient Protection and Affordable Care Act (ACA)

- ACA sets out an intent through legislation.
  - Assure near-universal, stable, and affordable coverage by leveraging and improving existing public and private health insurance
  - Increase role of prevention and its integration into health care and community
  - Promote cross-payer efficiency
  - Note that intent was to improve access, not necessarily to improve payment to providers
  - While improving payment can improve access, that is not the primary motivation in ACA

HHS enforces that intent through regulation

Individual Coverage Required

- Effective January 2014, most Americans required to have coverage or pay a fee
  - Fee is greater of $695 per person ($2085/family) or 2.5% of household income
  - Some exceptions, such as for financial hardships, religious objections, persons for whom the lowest cost health plan exceeds 8% of income
  - Advance refundable tax credits and cost-sharing assistance available up to 400% of federal poverty level (FPL)
  - Employers not mandated to provide coverage but there are penalties for not doing so
Private Insurance and Group Health Plans

- Pre-2014 ACA reform mandates provision of ACIP-recommended vaccines at no cost-sharing
  - >190 million privately insured people will have access to ACIP-recommended vaccinations
  - Must cover adult children up to age 26 years who have no health insurance (from 2014, it is regardless of coverage)
  - No pre-existing conditions for children <18 years
  - Insurers must implement new ACIP-recommendations within a year of CDC adoption
  - No plan is required to cover vaccinations delivered by an out-of-network provider
    - Plans that do cover out-of-network provider can do so at out-of-network cost-sharing standards

Self-Insured Group Health Benefit Plans (ERISA Plans)

- ACA also extends many of its standards to the self-insured ERISA group health plans
  - In particular, all ERISA plans are subject to the ACA's standards on preventive services coverage
  - Thus, must cover all ACIP-recommended vaccines at no cost-sharing
  - Some plans are grandfathered in the ACA…

What Are Grandfathered Plans?

- State-regulated private health insurance sold in individual and group health markets are grandfathered into the ACA
  - Routine changes can be implemented:
    - Cost adjustments consistent with medical inflation
    - Addition of new benefits
    - Modest adjustments to existing benefits
    - Voluntarily adopting new patient protections established under ACA
    - Changes to comply with state or federal requirements
What Are Grandfathered Plans?

- Grandfathered status is lost if:
  - Plans reduce or eliminate existing coverage
  - Plans increase deductibles or co-payments by more than rate of medical inflation plus 15%
  - Plans require patients to switch to another grandfathered plan with fewer benefits or higher cost-sharing to avoid new patient protections implemented by ACA
  - Plans are acquired by or merge with another plan to avoid complying with ACA
  - In 2011, 50% of plans had grandfathered status
    - Half more expected to lose that status by 2012
    - Small plans likely to lose status quicker than large plans

Still, Grandfathered Plans Must Immediately...

- Have no lifetime limits
- Have no rescissions
- Include coverage for adult children up to 26
- Not deny coverage for children with pre-existing conditions effective 2010; all others, effective 2014
- Implement a 90-day limit on waiting periods
- Provide uniform explanation of coverage
- Implement medical loss ratio and rebates
  - Spend 80% to 85% of premium dollars on medical care and health care quality improvement, not administrative costs, starting in 2011; otherwise, provide a rebate to their patients, starting in 2012

State-Regulated Health Insurance

- ACA established market standards for state-regulated health insurance (eg, coops, FEHBP) regardless whether through an exchange or in open market
- Essential health benefits, including preventive services, must be covered
- State health insurance exchanges must be established by 2014 for small businesses
- All state-regulated, non-grandfathered insurance plans must include ACIP-recommended vaccines at no cost-sharing
Medicaid and CHIP

• Effective 2014, all non-elderly persons with incomes up to 133% FPL, based on "modified adjusted gross income," are Medicaid eligible
  • States required to benchmark coverage to newly eligible enrollees, including immunization services to children and adults
  • Makes a considerable number of Americans eligible for Medicaid benefits by increasing not only the income but the gender and family position eligibility criteria
  • Increased coverage for immunizations for newly eligible enrollees

Medicaid and CHIP

• Medicaid payment increase for primary physician services to 100% of Medicare payment rates; 100% FMAP for state payment increment for first 2 years
  • Increases immunization administration fee to Medicare levels for two years: 2013 and 2014
  • Opportunity to show importance of adequate payment on coverage
  • States that cover ACIP-recommended vaccines and administration costs with no cost-sharing will receive a 1% increased FMAP, beginning in 2013

Medicare: Effective From 2011

• All Medicare beneficiaries receive a personalized prevention plan that incorporates ACIP-recommended vaccines
• All cost-sharing eliminated for services under said personalized prevention plan
• Any preventive service received in outpatient setting in hospital paid for at 100%
  • Improves access to immunizations provided under Part B of Medicare
• GAO study on impact of Medicare Part D payment on access to immunizations
  • Highlighted access problems with adult vaccine covered under Part D
  • Urges appropriate steps to address administrative challenges (e.g., verifying beneficiaries’ coverage)
Federal Funding for Immunization Programs
- Section 317 program was reauthorized
  - A $100 million increase for the Section 317 program was provided for out of the Prevention and Public Health Fund for 2011; 2012 has a $29 million cut...
- States are permitted to purchase adult vaccines with state funds at CDC-negotiated rates
  - Impact unclear on whether exchange plans will benefit; may be considered private/public partnership?
- Demonstration programs to improve immunization coverage through the use of evidence-based and population-based interventions
  - Provides opportunity to implement broad range of innovative initiatives

Community Health Centers (CHC)
- Community Health Center Fund established, $11 billion over 5 years to expand CHC operations
- CHCs eligible to participate in pilot and demonstration projects from the Center for Medicare and Medicaid Innovation
- Number of patients served expected to double to 35 million by 2019
  - Increases access to immunizations for millions of children and adults in medically underserved communities
  - Underinsurance still an issue until full implementation of the ACA

Moving Forward...
- ~24 million will remain uninsured so public health safety nets are still necessary
- Improving access for the newly insured
  - Disproportionately lower income and residents of medically underserved communities
- Potential for lag time in health plan implementation of updated ACIP recommendations?
- How do health plans implement new coverage once added?
  - While payment may not be an issue, adequacy of provider payment for vaccines and administration remains?
- Continuing Medicare B/D challenge
- Medicaid preventive coverage for traditionally eligible persons
Moving Forward

- Changing nature of community efforts in light of near-universal coverage
- Building immunization into pilots and demonstrations
- None of community transformation grants awarded for IZ
- Health plan quality performance measures
- Community prevention and public health organization, financing, and operations with near-universal coverage will evolve
- Third-party billing – CDC “billables” project
- Integrating adult IZ into prevention efforts
- Making adult IZ standard of care requires development of preventive care infrastructure to deliver the vaccines
- An Adult Annual Wellness Visit?

Thank you for your attention!

Questions?

Email: litjen.tan@ama-assn.org
Website: www.ama-assn.org/go/adultvaccines
WORKGROUP

Chairperson
R. Gordon Douglas, Jr., MD
Adjunct Professor of Medicine
Weill Cornell Medical College
New York, New York

Paul Etkind, DrPH, MPH
Senior Director of Infectious Diseases
Community Health Team
National Association of County and City Health Officials
Washington, DC

Stefan Gravenstein, MD, MPH
NAVP Program Director and GSA Member
Professor of Medicine and Professor of Health Services, Policy, and Practice
Alpert Medical School of Brown University
Clinical Director
Healthcentric Advisors
Providence, Rhode Island

Walter A. Orenstein, MD
Professor of Medicine
Associate Director, Emory Vaccine Center
Director, Emory Program for Vaccine Policy and Development
Program Director for Operations Management and Initiatives, Influenza Pathogenesis and Immunology Research Center
Emory University School of Medicine
Atlanta, Georgia

Barbara Resnick, PhD, RN, CRNP, FAAN, FAANP
GSA Member
Professor of Nursing
University of Maryland School of Nursing
Adjunct Professor
Department of Epidemiology and Preventive Medicine
University of Maryland School of Medicine
Baltimore, Maryland

William Schaffner, MD
Professor and Chair, Department of Preventive Medicine
Professor of Medicine (Infectious Diseases)
Vanderbilt University School of Medicine
Nashville, Tennessee
Summit
Washington Hilton • Washington DC
Wednesday and Thursday, April 25-26, 2012

SPEAKERS

Gregory Poland, MD
Director, Vaccine Research Group
Mayo Clinic

Joseph Fortuna, MD
Vice-Chair
Michigan Primary Care Consortium

Litjen (LJ) Tan, PhD
Director, Medicine and Public Health
American Medical Association
PARTICIPANTS

Alpert Medical School of Brown University
Stefan Gravenstein, MD, MPH
Professor of Medicine and Professor of Health Services, Policy, and Practice

American Academy of Physician Assistants
Leocadia Conlon, PA-C, MPH
Senior Fellow Research and Public Health

American Immunization Registry Association
Alison Chi, MPH
Program Coordinator

American Medical Association
Litjen (LJ) Tan, PhD
Director, Medicine and Public Health

American Nurses Association
Katie Brewer
Senior Policy Analyst

American Pharmacists Association
Mitchel C. Rothholz, RPh, MBA
Chief Strategy Officer

Association of Immunization Managers
Claire Hannan, MPH
Executive Director

Association of State and Territorial Health Officials
Kathryn L. Talkington
Senior Director, Immunization and Infectious Disease Policy

Baltimore City Health Department
Anne Bailowitz, MD, MPH
Assistant Commissioner, Clinical Services

Centers for Disease Control and Prevention
Carolyn B. Bridges, MD
Associate Director, Adult Immunization

Cervical Cancer-Free America
Sara B. Smith, MSW, MSPH
Project Coordinator

Emory Vaccine Center
Walter A. Orenstein, MD
Director, Vaccine Policy and Development

Gerontological Advanced Practice Nurses Association
Hope Miller, MS, GNP-BC
Director of Advanced Illness

GlaxoSmithKline
Thais McNeal
Director, Healthy Communities & Alliance Development, Public Policy and Advocacy

GlaxoSmithKline
Shelly O'Donovan
Vaccine Policy and Advocacy Development

Healthcentric Advisors
Rosa Baier, MPH
Senior Scientist

HHS – National Vaccine Program Office
Angela K. Shen, ScD, MPH, CAPT
U.S. Public Health Service Director, Vaccine Policy and Development

Immunization Action Coalition
Laurel Wood
Coordinator for Public Health

Infectious Diseases Society of America
Irene Stephens
Program Officer for Health Policy

Maryland Partnership for Prevention
Tiffany Tate, MHS
Executive Director
Mayo Clinic
Gregory Poland, MD
Director, Vaccine Research Group

Merck Vaccines
Eddy A. Bresnitz, MD, MS
Medical Director, Adult Vaccines, Global Medical Affairs and Policy

Merck Vaccines
Bindi I. Patel, MPH
Region Policy Executive

Michigan Primary Care Consortium
Joseph Fortuna, MD
Vice-Chair

National Association of County and Health Officials
Paul Etkind, DrPH, MPH
Senior Director of Infectious Diseases

National Committee for Quality Assurance
Mary Barton, MD, MPP
Vice President

National Council on Patient Information and Education
Ray Bullman
Executive Vice President

National Foundation for Infectious Diseases
Len Novick, MA
Executive Director

National Gerontological Nursing Association
Amy Cotton MSN, GNP-BC, FNP-BC, FNGNA
President

Omnicare, Inc.
W. Gary Erwin, PharmD
Senior Vice President, Clinical Services
President, Omnicare Senior Health Outcomes

Pfizer
Dial Hewlett Jr., MD, FACP, FIDSA
Sr. Director, Team Leader
U.S. Medical Affairs - Vaccines
Medicine Development Group

sanofi pasteur
Stuart Feldman, MSc
Director of Global Advocacy and Public Policy

sanofi pasteur
Susan Awad
Government Relations and Immunization Policy intern

The Gerontological Society of America
Nancy Whitelaw, PhD
President

The Gerontological Society of America
Stefan Gravenstein, MD, MPH
Professor of Medicine and Professor of Health Services, Policy, and Practice

The Gerontological Society of America
Barbara Resnick, PhD, RN, CRNP, FAAN, FAANP
Professor of Nursing

University of Maryland
Barbara Resnick, PhD, RN, CRNP, FAAN, FAANP
Professor of Nursing

Vanderbilt University School of Medicine
William Schaffner, MD
Chair, Department of Preventive Medicine
Professor of Infectious Diseases

Weill Cornell Medical College
R. Gordon Douglas, Jr., MD
Adjunct Professor of Medicine

GSA Team
James Appleby, RPh, MPH
Executive Director

Kelly Barland
Facilitator

Carly Bushong
Meetings and Education Coordinator

Fay Gallagher Christenson
Senior Manager of Meetings and Education

Stefan Gravenstein, MD, MPH
Health Sciences Section Member

Judie F. Lieu
Director, New Product Development

Patti Manolakis, PharmD
Facilitator

Annette M. Schmidt
Director, Strategic Alliance Development

Jann Skelton, RPh, MBA
Facilitator

THE GERONTOLOGICAL SOCIETY OF AMERICA
PARTICIPANT BIOS

Susan Awad
Susan Awad is a Government Relations and Immunization Policy intern with Sanofi Pasteur, one of the largest vaccines manufacturer in the world. She is responsible for researching issues related to adult immunization and communicating the findings to senior franchise and advocacy leaders; reporting on international developments in vaccine research and financing; and assisting with communications, strategic planning, and research management. Before joining SP, Ms. Awad was a Presidential Management Fellow at National Institutes of Health. She is currently studying health policy at The George Washington University, and she holds a M.A. in economics from the University of Virginia and a B.A. in economics from the University of Florida.

Rosa Baier, MPH
Rosa Baier is Senior Scientist at Healthcentric Advisors, a quality improvement agency in Providence, Rhode Island. She is also Teaching Associate at the Warren Alpert Medical School of Brown University and the CDC-designated Healthcare-Associated Infections (HAI) Coordinator for the state of Rhode Island. Ms. Baier has 10 years of experience in applied health care research, focusing specifically on health care measurement, reporting, and quality. For the Rhode Island Department of Health, she directs the health care quality reporting program, which publicly reports clinical quality and satisfaction for providers across all settings. The program’s public reports include hospital HAI data, such as employee influenza vaccination rates and various infection rates. Ms. Baier collaborates with providers and researchers to implement and evaluate sustainable systems change that improves care and experience for vulnerable patients. Her successes include creating care transitions best practices and measures, then aligning provider implementation with health plan contracting. In addition to immunization and HAI reporting, her research interests include the association between providers’ goal selection and performance, improving care transitions, and reducing unnecessary health care utilization. Ms. Baier received her bachelor of arts degree from Wellesley College in 2000 and her master of public health in 2004 from Brown University.

Anne Bailowitz, MD, MPH
Anne Bailowitz is a board-certified pediatrician, currently serving as Assistant Commissioner of Clinical Services at the Baltimore City Health Department.

Dr. Bailowitz attended Harvard University, studied medicine at Stanford, completed her pediatric residency and master of public health at Johns Hopkins, and was an infectious disease epidemiology fellow at the National Institutes of Health’s National Institute of Allergy and Infectious Disease. She practiced pediatrics for 12 years and transitioned to public health through experiences at the state health department (first pediatric epidemiologist) and the Baltimore County Health Department (Medical Director). In addition, she is on the faculty of the University of Maryland.

During her time at the Baltimore City Health Department, Dr. Bailowitz has filled many positions. Starting as Chief of Child Health and Immunization in 2001, Dr. Bailowitz collaborated to raise Baltimore’s school immunization coverage to 99.7%, up from approximately 65% in the 1980s and 1990s. Statistics for pre-
schoolers also improved: coverage for 19- to 35-month-old children increased by 17.8% (2001-2004). The Immunization Program’s achievement was recognized in 2006 with an improvement award from the Centers for Disease Control and Prevention (CDC). As the Health Department’s Chief Medical Officer, she led the city’s medical response to H1N1. Over 42,000 citizens were immunized against H1N1 and seasonal influenza through the combined efforts of all programs of the City Health Department in close collaboration with city agencies; academic, business, and media partners; and state and federal government.

Since April 2011, as Assistant Commissioner of Clinical Services, Dr. Bailowitz has focused on defining and developing a new bureau of clinical services in the context of health care reform. The bureau joins public health clinics which offer services across the lifespan: immunization; adolescent and reproductive health; STD/HIV/TB; and oral health. The goal is to provide the highest quality public health clinic services as economic and health care realities and reforms continue to evolve.

Advocacy for local public health continues as she presents the city’s interests to the National Association of County and City Health Officials, the CDC, the National Vaccine Advisory Committee, and the Institute of Medicine. Dr. Bailowitz is the author of numerous articles and abstracts on influenza, pediatric immunization, and the role of local public health in adult immunization. Her greatest professional satisfaction comes from mentoring students of all ages as they explore the opportunities offered by a career in public health and medicine.

Kelly Marie Barland
Kelly Marie Barland began her career working 7 years in the insurance industry, gaining knowledge of Medicare Advantage, Medicare supplement, and Part D plans. She earned a bachelor of science in Biology from Westminster College in Utah and will graduate next month with a doctor of pharmacy degree from Wingate University School of Pharmacy in North Carolina. She has trained with clinical pharmacists who specialize in immunizations, diabetes, and medication therapy management (MTM), and is currently completing an advance practice experience in consulting on health policy, education, and strategic problem solving. She has organized local immunization clinics and health fairs, and presented on clinical and leadership programs. Ms. Barland has held numerous leadership positions at Wingate University and serves as the National Student President of the Pharmacist Society, a networking site for pharmacy professionals.

Mary Barton, MD, MPP
Mary Barton is Vice President for Performance Measurement at the National Committee for Quality Assurance (NCQA). She oversees the team supporting new quality measure development and the upkeep of existing measures in the HEDIS measure set. Prior to joining NCQA, Dr. Barton was for over 5 years Scientific Director of the U.S. Preventive Services Task Force (USPSTF) at the Agency for Healthcare Research and Quality (AHRQ). In that role, Dr. Barton’s responsibilities included overseeing the evidence reviews prepared for the USPSTF by AHRQ-supported Evidence-based Practice Centers as well as support and oversight of the methodologic and recommendation-making work of USPSTF.

Dr. Barton trained in primary care internal medicine at Brigham and Women’s Hospital in Boston, and she completed a general medicine research fellowship at Harvard. Prior to joining AHRQ, she was an assistant professor at Harvard Medical School, where she performed clinical epidemiology and health services research related to cancer screening and prevention in terms of access, test performance, and outcomes. She is a member of the American College of Physicians and the Society of General Internal Medicine.

Dr. Barton received her doctor of medicine degree from Harvard University and a master’s degree in public policy from the Kennedy School of Government at Harvard.
Eddy A. Bresnitz, MD, MSCE, FACP
Eddy Bresnitz is a board certified internist, pulmonary and preventive medicine physician, and currently is Global Medical Director for Adult Vaccines, Global Medical Affairs and Policy, at Merck Vaccines. In his position at Merck, Dr. Bresnitz is a member of several product development teams; serves as the principal liaison to the ACIP/CDC and other professional organizations for influenza, herpes zoster, and adult hepatitis issues; moderates and participates on the Global Adult Vaccine Advisory Board; organizes, moderates, and participates in Global Expert Input Forums and international symposia; and supports the adult marketing franchise.

Previously, Dr. Bresnitz served as the Deputy Commissioner for the Public Health Services Branch (2005-2008) and Chief (State) Epidemiologist in the New Jersey Department of Health and Senior Services (1999-2008). He led many emergency response efforts, including the West Nile virus outbreak, the 2001 anthrax attack, the smallpox vaccination program, the SARS outbreak, influenza pandemic preparedness, and others. Prior to joining New Jersey state government, Dr. Bresnitz was a faculty member (1983-1999) at the MCP Hahnemann (now Drexel University) School of Medicine in Philadelphia, serving for many of those years as Professor and Chairman of the Department of Community and Preventive Medicine. He is currently Adjunct Professor of Epidemiology in the University of Medicine and Dentistry of New Jersey School of Public Health.

Dr. Bresnitz received his medical degree from McGill University in Montreal in 1974, followed by an internship and residency in internal medicine at Montefiore Hospital in New York City. He then served as Director of Emergency Services at the Brooklyn Hospital (1977-1980). He completed fellowships in pulmonary medicine and clinical epidemiology at the University of Pennsylvania, where he received a master’s degree in clinical epidemiology. He is a past president of the Council of State and Territorial Epidemiologists and was a member of the Infectious Disease Committee of the Association of State and Territorial Health Officials. Dr. Bresnitz has served on several national committees focused on preparedness efforts for influenza pandemics and bioterrorism. He also has served on advisory committees to the National Quality Forum on harmonization of quality measures. He has published extensively in peer-reviewed journals on a variety of public health topics and has received several recognition awards for his teaching and public service.

Ray Bullman
Ray Bullman joined the National Council on Patient Information and Education (NCPIE) in 1985. He has served as Executive Vice President since January 1995. NCPIE, organized in 1982, is a non-profit coalition of diverse member organizations working together to stimulate and improve communication of information on safe and appropriate use of medicine to consumers and health care professionals.

Alison Chi, MPH
After 8 years of scheduling commercials for a New York radio station, Alison Chi earned a master of public health degree from Hunter College. She began provider outreach activities for the Citywide Immunization Registry (CIR) at the New York City (NYC) Department of Health and Mental Hygiene in 1997. In 2004, Ms. Chi left the CIR to become a senior administrator for a data collection system used by community-based organizations receiving over $100,000,000 in funding from the Centers for Disease Control and Prevention and the Health Resources and Services Administration to provide services to people living with HIV/AIDS. Two years ago, she returned to her roots in the immunization information system (ISS) arena, first working as Director of EHR-IIS interoperability for the NYC CIR, and now as Program Coordinator for the American Immunization Registry Association.
J. Leocadia Conlon, PA-C, MPH

Leocadia is a Physician Assistant with 11 years of clinical experience, which includes practice in hepatology, internal medicine, and family medicine. Her clinical practice experience includes clinical research for inquiries related to hepatitis B, hepatitis C, hepatocellular carcinoma, liver transplant, and non-alcoholic steatohepatitis. She holds a master of public health degree from Johns Hopkins Bloomberg School of Public Health. She is a passionate patient advocate and seeks opportunities for patient education and outreach, and to broaden access to medical care among the underserved. To this end, she recently served pro bono as project manager for a start-up non-profit maternal child health care organization based in Hawaii. In addition, she led an adult vaccine education initiative in her family medicine practice from 2009-2010 in Hawaii. In her current role as Senior Fellow in Science and Public Health, she is involved in: disseminating information regarding best practice guidelines to physician assistants throughout the United States; promoting and supporting physician assistants in patient outreach activities and participating in the development of new learning programs to advance physician assistant knowledge and impact on patient health outcomes.

Amy Cotton, MSN, GNP-BC, FNP-BC, FNGNA

Amy Cotton is the Eastern Maine Healthcare System (EMHS) Director of Operations and Senior Services Quality in the Continuum of Care division. EMHS is located in Brewer, Maine, and is an organized health system of seven hospitals, seven long-term care facilities, a retirement community, home and hospice care, and primary health care practices. Ms. Cotton has a blended clinical leadership and practice role as a gerontological nurse practitioner, providing primary care for older adults in assisted living, home, and nursing home settings. She has quality program development and outcomes responsibilities for older adults in non-acute settings of health care delivery. She also participates in clinical research and system initiatives to improve health outcomes of older adults in the state of Maine.

Ms. Cotton is currently President of the National Gerontological Nursing Association (2011-2013) and is actively engaged in numerous regional and national efforts to improve the quality of nursing care and health service delivered to older adults and their family caregivers. She was the inaugural recipient of Sigma Theta Tau International Honor Society of Nursing 2009 Geriatric Nursing Leadership Award and is a fellow of the National Gerontological Nursing Association.

R. Gordon Douglas, Jr., MD

R. Gordon Douglas is currently Adjunct Professor of Medicine at Weill Cornell Medical College; Chairman of Aeras (formerly Aeras Global TB Vaccine Foundation), a non-profit biotech company; Director of three biotech companies: Vical, Inc. (Chairman), Novadigm (Chairman), and Protein Sciences. Dr. Douglas served as a consultant to the Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), from 1999-2011. He retired from Merck & Co. in 1999 after serving as President, Merck Vaccine Division, and a member of its Management Committee for 9 years.

Dr. Douglas is a graduate of Princeton University (1955) and Cornell University Medical College (1959). After internal medicine training at the New York Hospital and Johns Hopkins Hospital, and infectious disease training at NIAID, he served successively as Head of the Infectious Disease Unit, University of Rochester, (1970-1982) and Chairman, Department of Medicine and Physician-in-Chief at New York Hospital Cornell Medical Center (1982-1990) before joining Merck. He is author of over 190 original scientific publications dealing with viral pathogenesis, vaccines, and anti-virals, and was co-editor (with Gerald Mandell and John Bennett) of Principles and Practices of Infectious Diseases, the standard reference in the field. He is recipient of the R.R. Hawkins Award (Association of American Publishers, 1980), the H. Feldman Award (Infectious Disease Society of America, 1992), and the Maxwell Finland Award (National Foundation for Infectious Diseases, 2000). He is a member of the Institute of Medicine, the Association of American Physicians, the American Society of Clinical Investigation, and the American Clinical and Climatologic Association. He recently retired as trustee of McCarter Theater, the National Foundation for Infectious Diseases, and the Lyme Academy College of Fine Arts. He served as President of the Class of 1955 at Princeton University from 2005 until 2010.
W. Gary Erwin, PharmD

W. Gary Erwin, PharmD, is Senior Vice President, Clinical Services, of Omnicare, Inc., and President of Omnicare Senior Health Outcomes. Dr. Erwin leads the development, implementation, and integration of patient-directed, evidence- and quality-based clinical programs into the daily operations of Omnicare. He directs a staff of approximately 800 clinicians conducting federally mandated consultant pharmacist services and medication regimen review in long-term care facilities, therapeutic interchange programs, medication therapy management, point-of-sale adjudication, and rejected claim resolution.

Dr. Erwin received his bachelor of science in pharmacy from Auburn University in 1976 and his doctor of pharmacy degree from the University of Kentucky in 1981. He also completed a hospital pharmacy residency at the University of Kentucky Medical Center in 1981. Prior to joining Omnicare, Dr. Erwin served as Vice President for Professional Programs and Professor of Clinical Pharmacy at the Philadelphia College of Pharmacy and Science. In addition, he was on the faculty at the University of Georgia, where he specialized in geriatric pharmacotheraphy and long-term care.

Stuart Feldman

Stuart Feldman is the Director of Global Advocacy and Public Policy for Sanofi Pasteur, one of the largest vaccines manufacturers in the world. In this capacity, Mr. Feldman is responsible for developing strategic alliances to promote immunization; managing major research projects designed to understand the value of vaccines worldwide and the impact of public policy on demand for preventive services; and delivering key policy messages to US Government Agencies. Prior to joining SP, Mr. Feldman studied and worked for many years in Asia. He is a former Foreign Policy Legislative Aide to Senator Orrin Hatch (UT) and consultant to the National Security Council. Mr. Feldman holds a M.Sc. in international relations from the London School of Economics.

Joseph Fortuna, MD

Joseph Fortuna is the Co-Founder and CEO of PRISM, a non-profit corporation providing a sustainable transformative services to medical practices. He is also the current Chair of the Health Care Division of the American Society for Quality, Vice-Chair of the Michigan Primary Care Consortium (MPCC), and a member of the MPCC Executive Committee. He also serves as a member of the Patient Centered Primary Care Coalition (PCPCC) Executive Committee.

Dr. Fortuna was a Divisional Medical Director of the Delphi Corporation, where he supervised the medical and occupational health activities in 73+ facilities worldwide, and where (with the use of process improvement tools) he directed the design, development, and implementation of Delphi’s Corporate Medical-Safety-Workers Comp Health Information System. He has served as the Speaker of the House of Delegates of the American College of Occupational and Environmental Medicine and as a member of its Board of Directors.

Stefan Gravenstein, MD, MPH

Stefan Gravenstein is a geriatrician, former John Franklin Chair of Geriatrics, and Director of the Glennan Center for Geriatrics and Gerontology at Eastern Virginia Medical School (1996-2007), now Associate Division Chief for Geriatrics at University Medicine. Dr. Gravenstein has a long-standing interest in immunity, inflammation, and aging—especially in the context of influenza and nursing home care—and the topic of the majority of his publications. He also has a specific interest in quality improvement in health care, the culture of care, and how to improve care across care transitions. Dr. Gravenstein is Clinical Director at Quality Partners of Rhode Island, Medicare’s Quality Improvement Organization for Rhode Island, where he works with a team to improve patient safety and care transitions. At Brown University, he works with the Department of Community Health (Mor, PI; Gozalo) and Pop-Vicas on evaluating the impact of influenza vaccine on outcomes in long-term care.
Claire Hannan, MPH
Claire Hannan is Executive Director of the Association of Immunization Managers, a membership association representing the 64 state, territorial, and large urban area immunization programs that receive direct federal grant funding from the Centers for Disease Control and Prevention. She has been in this position since February of 2004. Previously, Ms. Hannan directed an immunization policy project for 7 years at the Association of State and Territorial Health Officials. She also served as an advocate for children’s health issues for 2 years at Capitol Associates Inc. Ms. Hannan began her career on Capitol Hill, working for Senator Barbara A. Mikulski (D-MD) for 5 years. Ms. Hannan holds a bachelor of arts degree in political science from Wagner College in Staten Island, New York, and a master of public health from Johns Hopkins University in Baltimore, Maryland.

Patti Gasdek Manolakis, PharmD
Patti Gasdek Manolakis is President of PMM Consulting LLC, a company focused on advancing healthcare quality by informing health policy, effecting positive change, enhancing the education and continuing professional development of health professionals, and engaging in projects to improve public health and medication use in a rapidly evolving, quality-focused, patient-centered healthcare system. Dr. Manolakis earned her Doctor of Pharmacy from Mercer University and practiced as a clinical pharmacist in a community hospital in suburban Atlanta. As a staff member for the American Pharmacists Association (APhA) in the 1990s, she first directed student development and professionalism initiatives, then served as Director of Therapeutics Resources, spearheading APhA’s clinical guidelines initiative. In this role, she convened and facilitated interdisciplinary panels of disease state experts to develop 42 disease-based decision-support tools and served as editor of the APhA Guide to Drug Treatment Protocols.

Dr. Manolakis has collaboratively powered national interdisciplinary summits focused on finding innovative solutions to long-standing challenges in pharmacy education and healthcare. She engages in policy, education, and collaborative initiatives to expand opportunities for pharmacists to enhance patient care and gain specialty recognition. Dr. Manolakis is also known for her research and outreach about the public health issues associated with drugs marketed without FDA approval, publishing and speaking on this topic nationally. In 2009, she was named by the Academy of Managed Care Pharmacy (AMCP) as the recipient of the AMCP Individual Contribution Award for her work to raise awareness of marketed unapproved drugs.

Hope Miller, MS, GNP-BC
Hope Miller is the Director of Advanced Illness at XL Health. XL Health is the largest special-needs plan in the United States that is focused on the care of chronically ill Medicare beneficiaries. From 2004-2011, Ms. Miller worked at Evercare, a division of United Healthcare. Her most recent position at Evercare was Director of Health Services for the Mid-Atlantic region, where she oversaw the direct clinical operations for the institutional special-needs membership. She is currently a member of the State Advisory Council on Quality Care at the End of Life. Ms. Miller has been an active member of Gerontological Advanced Practice Nurses Association since 2004. She received her master of science degree from the University of Maryland at Baltimore.

Len Novick, MA
Len Novick has been Executive Director of the National Foundation for Infectious Diseases (NFID) since 1995. Prior to joining NFID, Mr. Novick was Vice President for External Business Development at the National Captioning Institute and Executive Director of the Conference of Educational Administrators Serving the Deaf. He also served as Project Director of the federally supported Captioned Films for the Deaf program. Mr. Novick received his bachelor of arts degree from Brooklyn College, his master of arts degree from Columbia University, and a Certificate of Advanced Graduate Studies in educational administration from Brooklyn College.
Walter A. Orenstein, MD

During his tenure at the National Immunization Program, Walter Orenstein led successful efforts to combat and markedly reduce the occurrence of once common childhood diseases, including measles, rubella, mumps, meningitis from *Haemophilus influenzae* type b, varicella, and invasive pneumococcal disease. The Immunization Program also made major contributions in protecting adults from vaccine-preventable diseases through eliminating barriers to vaccination and developing new vaccine strategies, expanding vaccine safety efforts, improving risk communication, and promoting the use of immunization registries.

Dr. Orenstein received his bachelor’s degree at The City College of New York and his medical degree from the Albert Einstein College of Medicine in 1972. He completed an internship and a residency in pediatrics at the University of California, San Francisco, followed by a fellowship in infectious diseases at the University of Southern California Medical School and a residency in preventive medicine at the Centers for Disease Control and Prevention (CDC). He has served in leadership roles within the CDC’s immunization program since 1982, and from May 1993 through January 2004, had been Director of the National Immunization Program. He has served as a consultant to the World Health Organization (WHO) and to the Pan American Health Organization for programs in polio eradication, measles control, and smallpox eradication in India, Brazil, Argentina, and Peru.

Dr. Orenstein has served as an Assistant Surgeon General of the U.S. Public Health Service, and he currently serves as Chairman of the WHO Technical Consultative Group on the Global Eradication of Poliomyelitis. He was a member and rapporteur of the Pan American Health Organization’s Technical Advisory Group on Vaccines and Immunization and served as the CDC liaison member to the National Vaccine Advisory Committee for more than 14 years, having played a major role in development of critical immunization policy documents such as “The measles epidemic: the problems, barriers and recommendations” (*JAMA*. 1991;266:1547-1552). This article became the blueprint for today’s immunization program including federal support for immunization infrastructure, an immunization coverage measurement system for program accountability, and the critical role of research in fostering immunization improvements. He also has served as CDC liaison to the American Academy of Pediatrics Committee on Infectious Diseases, the major immunization policy-making body for private pediatricians.

Bindi I. Patel, MPH

In her role as Region Policy Executive with Merck Vaccines Division, Bindi Patel has extensive experience working with state government officials, key vaccine advocates, and policy makers to support favorable vaccine policies in states. Ms. Patel has worked with Merck Vaccines Division for over 11 years holding positions in domestic and international marketing, marketing communications, and health policy analysis. Prior to joining Merck, she began her career with the Centers for Disease Control and Prevention in the Vaccine Safety Branch of the National Immunization Program. She was responsible for coordinating the Vaccine Identification Standards Initiative, a collaborative effort among key immunization partners to standardize identification information on vaccine packaging. Ms. Patel holds a bachelor of arts degree in psychology from North Carolina State University and a master of public health degree with a concentration in health behavior and health education from the University of North Carolina at Chapel Hill School of Public Health.
Gregory Poland, MD
Greg Poland is the Director of Mayo Clinic’s Vaccine Research Group, a state-of-the-art research group and laboratory that investigates issues surrounding vaccine response, vaccine policy, and novel vaccines important to public health. Dr. Poland is Professor of Medicine and Infectious Diseases, Director of the Immunization Clinic, and Director of the Program in Translational Immunovirology and Biodefense at the Mayo Clinic. He is the Editor in Chief for the journal Vaccine.

Dr. Poland is the recent recipient of the Mayo Clinic Department of Medicine Lifetime Research Achievement Award. In addition, he recently received a National Institutes of Health MERIT Award. Dr. Poland was awarded the Secretary of Defense Award for Excellence in December 2008. In 2008, he was named a Master of the American College of Physicians. Dr. Poland received the Hsu Prize in International Infectious Disease Epidemiology in 2007, and the Charles Merieux Lifetime Achievement Award in Vaccinology from the National Foundation for Infectious Diseases in May 2006. In December 2006, Dr. Poland was elected President of the Defense Health Board, serving two terms, and currently serves as the Vice President and advisor on pandemic influenza issues to the Secretary of Defense. In 2005, he was awarded an honorary Doctor of Humane Letters by Illinois Wesleyan University, his alma mater. He was appointed as the Mary Lowell Leary Professor in Medicine by Mayo Clinic’s Board of Trustees in 2004. In May 2003, he was awarded the Secretary of Defense Medal for Outstanding Public Service. Since 2004, Dr. Poland has served on the Infectious Diseases Society of America (IDSA) Taskforce on Pandemic Influenza, and chaired the American College of Physician’s Adult Immunization Advisory Board. Dr. Poland received the inaugural Gold Medal from the Spanish Vaccinology Society in 2001. In 1998, he received a joint award from the Centers for Disease Control and Prevention and the Health Care Financing Administration for his contribution to increasing adult immunization rates in the United States, which was awarded by the U.S. Surgeon General. In 1997, he was honored as the Outstanding Clinical Investigator of the Year by Mayo Clinic. Dr. Poland is the immediate Past President of the International Society for Vaccines, and is the current President and co-founder of the Edward Jenner Society.

Barbara Resnick, PhD, RN, CRNP, FAAN, FAANP
Barbara Resnick received a bachelor of science in nursing from the University of Connecticut, a master of science in nursing from the University of Pennsylvania, and a doctoral degree in nursing from the University of Maryland.

Dr. Resnick’s research focus has been on motivation of older adults, particularly with regard to performance of functional activities and engaging in regular exercise. Included among her research activities have been several federally funded projects focused on older adults such as Testing the Reliability and Validity of the Exercise Plus Program Post Hip Fracture (NIH R01 AG17082-01) and Testing the Effectiveness of the Res-Care Intervention (AHRQ R01 HS/MH 13372-010). In addition, Dr. Resnick has numerous projects focused on testing exercise interventions across a variety of clinical areas: community dwelling older adults in a continuing care retirement community and minority older adults in senior centers. Similarly, Dr. Resnick is the primary investigator on several measurement studies related to physical activity in older adults. She has authored over 100 manuscripts, numerous book chapters on both clinical and research topics relevant to the care of older adults, and she recently authored a book on restorative care nursing. Dr. Resnick is a fellow in the Academy of Nursing and the American Academy of Nurse Practitioners, received the 2003 Distinguished Faculty Research Award from the University of Maryland, and numerous awards for both her clinical work as well as her research.

Mitchel C. Rothholz, RPh, MBA
Mitchel C. Rothholz is a pharmacist currently serving as Chief Strategy Officer for the American Pharmacists Association (APhA). In his current position, he is responsible for the strategic oversight of Association initiatives including implementation of APhA’s Strategic Plan, evaluation and management of strategic alliances, establishment of Association policy and communications, and fostering collaborative partnerships within the Association as well as the external community. He also serves as Secretary for the Joint Commission of Pharmacy Practitioners. He is a 1984 graduate of the University of Florida College of Pharmacy, and he has worked as an association executive for more than
Mr. Rothholz is a nationally recognized expert on pharmacy-based immunization delivery, and serves as a national faculty member for APhA’s immunization certificate training program for pharmacists. He has given presentations to numerous community and professional groups on topics ranging from medication use to health care reform to immunizations. He is a member of his local disaster medical assistance team and has completed the Strategic National Stockpile Training Program. He is a member of several immunization coalitions and has served on the Steering Committee of the National Coalition on Adult Immunizations. He has been a participant on several Centers for Disease Control and Prevention (CDC) and Centers for Medicare and Medicaid Services task forces. He currently serves on the Executive Committee of the AMA/CDC National Influenza Vaccination Summit (NIVS), the Advisory Board of the Immunization Action Coalition, and the Department of Health and Human Services National Vaccine Advisory Committee’s Adult Vaccination Working Group. He currently serves as co-chair of the NVIS Payment Working Group, chair of the NVIS Awards/Recognition Committee, and is the lead on an APhA/CDC Cooperative Agreement. He has assisted numerous pharmacists in implementing immunization services and has made presentations to public policy makers and the media on pharmacy-based immunizations and immunizations across the lifespan. He has worked on projects involving collaboration among pharmacists, physicians, and other health care professionals leading to improved patient care outcomes.

William Schaffner, MD
William Schaffner is Chairman of the Department of Preventive Medicine as well as Professor of Infectious Diseases in the Department of Medicine at the Vanderbilt University School of Medicine. His primary interests are infectious diseases and their prevention. Dr. Schaffner has worked extensively on the effective use of vaccines in both pediatric and adult populations. He is a strong proponent of collaboration between academic medical centers and public health institutions.

Dr. Schaffner is a liaison representative to the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) and is a member of the Immunization Technical Advisory Committee of the American College of Physicians. He is a former member of the National Vaccine Advisory Committee (NVAC), Past President of the Society for Healthcare Epidemiology of America, and a former Councilor and Secretary of the Board of Directors of the Infectious Diseases Society of America. Currently, he is President of the National Foundation for Infectious Diseases. Dr. Schaffner is a consultant in public health policy and communicable disease control for numerous national and local institutions including the CDC, the World Health Organization, and the Tennessee Department of Health. Dr. Schaffner is a member of numerous professional societies and has written over 400 scientific articles and textbook chapters. He often is called upon to communicate about public health issues in the print media and television.

After graduation from Yale in 1957, Dr. Schaffner attended the University of Freiburg, Germany, as a Fulbright Scholar. In 1962, he graduated from Cornell University Medical College and completed an internship, residency training, and a fellowship in Infectious Diseases at Vanderbilt University Medical Center. He was commissioned in the U.S. Public Health Service as an Epidemic Intelligence Service Officer with the CDC in Atlanta for 2 years (1966-1968), returning to Vanderbilt after that tour of duty.

Angela K. Shen, ScD, MPH, CAPT
As the Director of Policy and Vaccine Development for the National Vaccine Program Office (NVPO), Angela Shen works on addressing barriers to vaccine development and innovation. Dr. Shen provides scientific advice and consultation to the Director of the NVPO to ensure that the department’s goals for vaccination and immunization are achieved, specifically related to vaccine financing and supply.

Before joining NVPO in 2006, Dr. Shen was a Senior Scientific Reviewer and Lead Inspector at the U.S. Food and Drug Administration (FDA) Center for Biologics
Evaluation and Research, where she reviewed over 100 biologics files and conducted more than 23 facility inspections domestically and overseas. Further, she has contributed to technical guidance documents as a regulatory expert in good manufacturing practices and quality systems management.

Dr. Shen has had broad experience in public health practice, regulatory science, and epidemiology and has held various scientific and policy positions at the FDA and the Centers for Disease Control and Prevention. She is a graduate of Tulane University School of Public Health and Tropical Medicine, Loma Linda University School of Public Health, and the University of California at Los Angeles. She holds the rank of captain as a commissioned officer in the U.S. Public Health Service.

Jann B. Skelton, RPh, MBA
Jann B. Skelton, President of Silver Pennies Consulting, has 25 years of experience in health care advocacy and communications. She has a diverse client background, working in pharmacy practice, healthcare consulting, pharmaceutical services, and professional advocacy organizations. Silver Pennies Consulting provides innovative services that deliver value to both consumers and health-related organizations by synching patient needs and business objectives.

Throughout her career, Skelton has served in many volunteer roles within the profession of pharmacy, including the APhA Foundation Advisory Board and the West Virginia University School of Pharmacy Visiting Committee. She is an adjunct faculty member for several schools and colleges of pharmacy. Skelton also served as a senior staff member for the American Pharmacists Association in Washington, DC for eight years.

She is a 1991 graduate of the West Virginia University School of Pharmacy and earned her MBA degree in 2000 from George Washington University.

Sara B. Smith, MSW, MSPH
Sara Smith is the Project Coordinator for Cervical Cancer-Free America, a multi-state initiative working to reduce or eliminate cervical cancer in the United States – state by state. Sara supports CCFA and its partner states through project coordination, coalition building, evaluation, development and other efforts related to CCFA’s goals. She comes to CCFA with experience in evaluation and assessment work on HPV vaccination and cervical cancer screening.

Irene Stephens
Irene Stephens joined the Infectious Diseases Society of America (IDSA) in January 2012 as Program Officer for Health Policy. At IDSA, she is responsible for all public health issues including adult and adolescent vaccine policy, antimicrobial stewardship, electronic health records, the National Health Safety Network, antimicrobial drug shortages, and antibiotic use in agriculture. She is also staffing IDSA’s National and Global Public Health Committee (NGPHC) and Antimicrobial Resistance Work Group (ARWG). Previously, Ms. Stephens worked for several years with the Association of State and Territorial Health Officials and most recently in the office of Rep. Bill Cassidy, a gastroenterologist from Louisiana. In 2006, she was a fellow in the Dr. James A. Ferguson Emerging Infectious Diseases Program at the Centers for Disease Control and Prevention, where she focused on pediatricians’ understanding and response to community-associated methicillin-resistant Staphylococcus aureus.

Kathryn L. Talkington
Kathy Talkington is the Senior Director for Infectious Disease and Immunization Policy for the Association of State and Territorial Health Officials. Ms. Talkington has been working in the public health policy field for the past 20 years covering a variety of issues at different levels of government and non-profit organizations. Her experience ranges from working at the Texas Department of Health as the Director of Federal Relations to serving as a consultant for the GAVI Alliance in Geneva, Switzerland. Ms. Talkington received her undergraduate degree from the University of Virginia and her master’s degree from the LBJ School of Public Affairs in Texas.
Litjen (LJ) Tan, PhD

LJ Tan is Director of Medicine and Public Health at the American Medical Association (AMA), where he leads multiple AMA efforts in immunizations and infectious diseases, prevention and health promotion, aging and community health, and eliminating health care disparities and improving the health of physicians. Until 2005, he was a part-time faculty member at Columbia College’s Institute for Science Education and Science Communication, where he received the 2000 Excellence in Teaching Award. He received his master of science in molecular biology from New York University, his doctoral degree in immunology/microbiology from Northwestern University Medical School, and completed a postdoctoral fellowship in molecular immunology at the University of Chicago Hospitals.

Dr. Tan currently is an elected member of the federal National Vaccine Advisory Committee, where he serves on the Adult Immunization, Vaccine Safety, and Healthcare Worker Immunization working groups. He is also a member of the federal Advisory Committee for Immunization Practices, where he serves on the influenza, pneumococcal, zoster, and adult immunization working groups, and of the federal Advisory Council for the Elimination of Tuberculosis, where he serves on the National Tuberculosis Program Workgroup. He serves on the Steering Committees for the 317 Coalition, the National Network for Immunization Information, the National Viral Hepatitis Roundtable, and on the Scientific Advisory Boards for the Immunization Action Coalition and the Coalition for Safe Community Needle Disposal. He co-founded and currently co-chairs the National Influenza Vaccine Summit, co-sponsored by the AMA and the Centers for Disease Control and Prevention (CDC), and founded and organized the first National Immunization Congress in 2007, and organized the second National Immunization Congress in 2010. He served as a primary consultant for the first European Union Influenza Summit and is an invited speaker for the second summit in 2012. A recognized leader in adult and influenza immunization policy, he continues to focus his immunization efforts on improving adult and adolescent immunization rates in the United States. Dr. Tan speaks on numerous issues ranging from vaccine financing to risk management in vaccine safety to emerging infectious diseases, and has served on numerous expert and technical advisory panels including panels for the Centers for Medicare and Medicaid Services, The Joint Commission, the CDC, for non-government organizations such Partnership for Prevention and the Centers for Disease Control and Prevention (CDC), and for various academic institutions. Dr. Tan has authored many peer-reviewed publications and has written numerous scientific reports to guide AMA policy on diverse public health topics. He has received several awards for his advocacy work and most recently was awarded the American Pharmacists Association’s national Immunization Champion Award. Dr. Tan is a member of numerous professional organizations including the American Public Health Association, the Federation of American Societies for Experimental Biology, the American Society of Microbiology, the American Association of Immunologists, the National Council of Asian & Pacific Islander Physicians, and the Infectious Diseases Society of America.

Tiffany Tate, MHS

Tiffany Tate is Executive Director of the Maryland Partnership for Prevention, a non-profit organization that is the parent organization to Maryland’s childhood and adult immunization coalitions. She is a Commissioner on the Maryland Advisory Commission on Immunization and a member of the National Association of County and City Health Officials’ Immunization Workgroup and the Planning Committee for the National Conference on Immunization and Health Coalitions.

Ms. Tate speaks and trains locally and nationally on coalition building, health literacy and plain language, diversity, community outreach, program planning and evaluation, and strategic planning. She possesses a certificate from the Health Literacy Institute and is a certified tutor with Literacy Advance. Ms. Tate has a master of health science from the Johns Hopkins University School of Hygiene and Public Health and bachelor’s degree in health administration from Texas Southern University. She is active in a number of community efforts, including serving as Co-Chair of the Enterprise Women’s Network Mentoring Program, a volunteer with Seasons Hospice, and a member of the boards of Quality Health Foundation and the Delmarva Foundation for Medical Care.
Nancy Whitelaw, PhD
Nancy Whitelaw is a nationally recognized leader in the design and implementation of evidence-based health programs for seniors and in strengthening collaboration among aging services, public health, and health care. Her work emphasizes the importance of prevention, self-management, and person-centered care, moving beyond the traditional medical model and into community settings, where most older adults live and wish to stay.

Under her direction, the National Council on Aging (NCOA) Center for Healthy Aging seeks to improve the health of older adults by strengthening collaboration between research and practice, and fostering improvements in programs, community partnerships, and public policy. The center’s work is especially focused on elders with multiple health problems and those at risk of frailty.

Dr. Whitelaw has a doctoral degree in health services organization and policy from the University of Michigan and bachelor of arts and master of science degrees in sociology from Portland State University. In 2004, she received NCOA’s Molly Mettler Award for national leadership in health promotion, and in 2007 she was awarded the Maxwell A. Pollack Award from The Gerontological Society of America for distinction in bridging research, policy, and practice. In 2009, she was the recipient of the Elizabeth Fries Health Education Award for “leading an innovative, effective nationwide movement to develop and deliver evidence-based health promotion and disease prevention programs through community-based, aging, and health organization networks.” Dr. Whitelaw was elected to serve as President of The Gerontological Society of America in 2012.

Laurel Wood
Laurel Wood is the Coordinator for Public Health with the Immunization Action Coalition. She has worked in a variety of public health communicable disease and epidemiology programs for almost 30 years. She recently retired after serving for 16 years as the Immunization Program Manager for the Alaska Division of Public Health. She also has served as the Chair of the Association of Immunization Managers and was the recipient of the organization’s 2007 Natalie J. Smith MD Award in recognition of excellence in immunization program management. For many years, she provided immunization training for students in the nursing/nurse practitioner programs at the University of Alaska Anchorage. Prior to moving to Alaska, Ms. Wood served for 14 years in a variety of roles with the Tennessee Department of Health, including Section Chief of Communicable and Environmental Disease Services and Director of the AIDS/HIV Program.
Summit
Washington Hilton • Washington, DC
Wednesday and Thursday, April 25-26, 2012

RECOMMENDED RESOURCE LIST


American Medical Directors Association. Immunizations in the Long-Term Care Setting Tool Kit. Available at http://amda.networkkats.com/members_online/members/viewitem.asp?item=LTCIMM3&catalog=LTCI&pn=1&af=AMDA.


